Increased serum brain-derived neurotrophic factor levels during opiate withdrawal

Zhang, Jie; Zhang, Xiangyang; Su, Hang; Tao, Jingyan; Xie, Ying; Han, Bin; Lu, Youming; Wei, Youdan; Sun, Huihui; Wang, Yue; Wu, Wenxin; Zou, Shengzhen; Hu, Liang; Zoghbi, Anthony W.; Tang, Wenjie; He, Jincai

doi:10.1016/j.neulet.2014.04.048

Cited by 39 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the present study, such elevated serum levels of BDNF in heroin users compared to healthy controls were previously reported during early abstinence in heroin-dependent patient without medical treatment [19,53], in heroin-dependent-patient receiving methadone [22,54], and in heroin addicts undergoing opioid withdrawal [16,21]. However, decreased serum levels of BDNF in heroin users were reported in other studies [15,17].…”

Section: Discussionsupporting

confidence: 92%

“…The results of preclinical studies indicate that experimental infusion of BDNF directly into the VTA produces drug seeking behaviour [10] and biochemical changes [14]. In clinical studies, decreased or increased BDNF levels have been found in heroin-dependent patients compared to healthy controls [15][16][17][18][19]. Furthermore, BDNF levels were found to be decreased in patients undergoing levomethadone or diamorphine maintenance treatment [20] but increased in patients during heroin withdrawal [21] and undergoing methadone maintenance treatment [22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users

Roviš¹,

Černelič-Bizjak²,

Vasiljev³

et al. 2018

Eur Addict Res

View full text Add to dashboard Cite

Background: This study has examined the relationships and interactions between serum brain-derived neurotrophic factor (BDNF) levels, BDNF Val66Met polymorphism and self-reported risk-taking behaviour in individuals with a history of heroin use undergoing outpatient treatment in comparison to healthy individuals. Methods: We enrolled 167 heroin users and 86 healthy subjects and examined serum BDNF levels, Val66Met polymorphism, and personal characteristics using Connor Davidson Resilience Scale, Risk-taking (RT) propensity questionnaire, and Personality Assessment Inventory. Results: Heroin users had significantly higher serum BDNF levels than controls. In addition, serum BDNF levels were significantly higher in Val/Val carriers than in Met/Val or Met/Met in all recruited subjects. Furthermore, a stepwise multiple regression analysis of serum BDNF levels as a dependent variable with related factors showed that in heroin users, Alcohol Use Disorder Identification Test score, anxiety and RT score were found as independent contributors to serum BDNF levels. When performing gene-environment interaction it was additionally found that heroin users with self-reported high risk-taking behaviour had significantly lower levels of serum BDNF among heroin users with the Met allele. Conclusions: These results indicate that genetic variant Met66 decreased the serum BDNF levels in combination with self-reported risk-taking propensity among heroin users. If results of future work confirm the influence of this combined effect between neurotrophic genotype and risk-taking behaviour, 66Met carriers might require higher levels of intervention to overcome their drug use pattern and risky behaviour.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users

Roviš¹,

Černelič-Bizjak²,

Vasiljev³

et al. 2018

Eur Addict Res

View full text Add to dashboard Cite

show abstract

“…As with methamphetamine literature, the results are inconsistent. Thus, while Angelucci et al (2007) and Zhang et al (2016) observed a significant decrease in serum BDNF levels in patients with history of chronic heroin abuse, in contrast Zhang et al (2014) observed increased levels in heroin-dependent patients during both early withdrawal (1-7 days) and 1 month after heroin cessation compared to healthy controls, a result consistent with those of Heberlein et al (2011) (Angelucci et al, 2007;Zhang et al, 2016, but see also Heberlein et al, 2011;Zhang et al, 2014). They found a positive correlation between peripheral BDNF levels and opiate craving in opiate-dependent patients.…”

Section: A Potential Biomarker?supporting

confidence: 52%

“…At this time in heroin-dependent patients, there have been four studies measuring levels of serum BDNF (Angelucci et al, 2007;Heberlein et al, 2011;Zhang et al, 2016Zhang et al, , 2014. As with methamphetamine literature, the results are inconsistent.…”

Section: A Potential Biomarker?mentioning

confidence: 99%

BDNF During Withdrawal

Geoffroy¹,

Noble²

2017

Vitamins and Hormones

View full text Add to dashboard Cite

“…Previous studies on BDNF suggest that alcohol and drug withdrawal may increase peripheral BDNF levels during several weeks [28,30,31,44]. However, since the plasma BDNF level was markedly higher in patients with substance use disorders, compared to the plasma BDNF level in the included patients, this exclusion may have influenced the results.…”

Section: Discussionmentioning

confidence: 93%

Plasma Brain-Derived Neurotrophic Factor and Psychopathology in Attempted Suicide

Ambrus¹,

Sunnqvist²,

Ekman

et al. 2016

Neuropsychobiology

View full text Add to dashboard Cite

Background/Aims: Increasing evidence suggests a link between brain-derived neurotrophic factor (BDNF) and suicidal behaviour (SB). Furthermore, decreased peripheral BDNF levels have been associated with clinical symptoms in various psychiatric disorders as well as with personality dimensions in healthy individuals. However, the relationship between BDNF and psychopathology is poorly investigated regarding SB. Methods: Plasma BDNF concentrations were analysed in 61 recent suicide attempters. Clinical symptoms were evaluated using the Comprehensive Psychopathological Rating Scale. Personality dimensions were assessed using the Marke-Nyman Temperament Scale. Results: Plasma BDNF correlated positively and significantly with the personality dimension Solidity but not with the other personality dimensions or with clinical symptoms. Conclusion: BDNF plays an important role in the regulation of neuroplasticity and neurogenesis in humans. Our results indicate that lower BDNF concentrations are associated with higher levels of impulsiveness and changeability (low scores on the Solidity scale). Furthermore, low plasma BDNF levels may be proposed as a trait marker rather than a state marker for attempted suicide.

show abstract

Increased serum brain-derived neurotrophic factor levels during opiate withdrawal

Cited by 39 publications

References 30 publications

Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users

Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users

BDNF During Withdrawal

Plasma Brain-Derived Neurotrophic Factor and Psychopathology in Attempted Suicide

Contact Info

Product

Resources

About